Investor Relations

High-growth company with focus on becoming a single-use pure player within all main endoscopy markets.

Latest news


Nov. 2019

Capital increase in connection with exercise of warrants (no. 3)

Ambu A/S issued 419,500 warrants in November 2016. Each warrant entitles the holder to subscribe for one Class B share with a nominal value of DKK 0.50 and 71 individuals participate in the 2016 scheme. The vesting period for the scheme is three years, and the scheme can therefore be exercised in the trading window that opened on 13 November 2019 in connection with Ambu’s financial report for 2018/19.

Since 13 November 2019, instructions have been received to exercise warrants as follows:

  • 2016 scheme: Five individuals have issued instructions to exercise a total of 40,000 warrants at the agreed exercise price of DKK 77.12 per share with a nominal value of DKK 0.50.

Today Ambu’s Board of Directors decided to carry out the capital increase relating to the exercised warrants.

As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 20,000 from DKK 125,904,800 to DKK 125,924,800 through the issue of 40,000 Class B shares.

Following this and in consideration of the employees having left the company, there are 364,500 remaining warrants under the 2016 scheme being held by 61 individuals.

The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 27 November 2019 under the ISIN code of Ambu A/S’ existing B shares (DK0060946788).

Under section 10 of the Danish Executive Order on disclosure requirements for issuers, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.

  Number of shares
(nominal value DKK 0.50)
Nominal value
Voting rights
A shares 34,320,000 17,160,000 343,200,000
B shares 217,529,600 108,764,800 217,529,600
Total 251,849,600 125,924,800 560,729,600

Download this announcement as pdf: Company announcement no 3 2019/20


Nov. 2019

Ambu A/S and Cook Medical collaboration update

Ambu A/S and Cook Medical Holdings LLC have decided to evolve their relationship in the field of duodenoscopy from a US* distribution agreement to a global marketing collaboration. This follows significant changes in the duodenoscope market, including FDA’s recommendation for U.S. hospitals to move to innovative technologies. We believe the new collaboration will benefit both parties.

The CEO of Ambu A/S, Juan Jose Gonzalez, says: “We have decided to lead the commercialization of our single-use duodenoscope through a direct sales force. We are excited about our collaboration with Cook Medical to support hospitals around the world in their transition to single-use duodenoscopy.

Barry Slowey, President of Cook Medical Endoscopy Division, says: “Cook Medical believes that single-use duodenoscopy is a cost-effective solution and we believe that Ambu is the right choice for hospitals to make this transition. We look forward to working with Ambu in enabling ERCP procedures to be done with single-use products.

No further details about the collaboration will be disclosed at this point. 

The single-use, sterile duodenoscope is currently being developed by Ambu to help address infections associated with cross-contamination. Since 2015, US regulatory authorities have increased their focus on potential endoscope cross-contamination, particularly that attributed to reusable duodenoscopes. Ambu’s single-use duodenoscope is expected to be available in the USA in early Q4 2019/20.

You can download this press release (pdf).

*Following FDA clearance of the device. Device is currently under development. Device not available for commercial sale or distribution in any jurisdiction.


Nov. 2019

Changes within the board of directors of Ambu A/S (no. 2)

Ambu A/S announces today that the chairman of the board of directors Jens Bager has informed the board of directors that after 9 years of service he wishes to resign from the board of directors. Jens Bager will resign as of Ambu’s annual general meeting in December 2019.

Ambu’s board of directors proposes that Lars Rasmussen is elected as new chairman of the board of directors at the annual general meeting. Lars Rasmussen is, among others, chairman of the board of directors of Coloplast A/S and H. Lundbeck A/S.

Furthermore, the board of directors proposes that Britt Meelby Jensen, CEO of the Swedish medtech company Atos Medical AB, is elected as new member of the board of directors at Ambu’s annual general meeting.

Commenting on his decision Jens Bager says: 

It is with pride that I now leave Ambu. During the years of my tenure as chairman of the board of directors, the company has multiplied its turnover as well as value and recently we have been successful in recruiting Juan Jose Gonzalez as new CEO. The company now faces a new journey that can make Ambu one of the top players within visualization.

Because of that, I have found this moment ideal to make room for new capabilities in the chairmanship which along with the remaining board members and management board can take Ambu to the next level.

I would also take the opportunity to thank my colleagues in the management board, the board of directors, Ambu’s shareholders and the company’s employees for having been able to act as chairman of the board of directors during a period in which the development of Ambu has been exceptionally positive.

Lars Rasmussen was born in 1959 and has vast experience within the medtech industry through a long career in Coloplast A/S in which he acted as CEO for 10 years. Lars Rasmussen is today chairman of the board of directors of Coloplast A/S and the pharmaceutical company H. Lundbeck A/S. Lars Rasmussen is also a member of the board of directors of the medtech company Demant A/S and holds further management level posts in Germination af 2008 ApS, ADO Holding af 26.02.2004 and a subsidiary of the latter. 

Britt Meelby Jensen (born 1973) has extensive experience in the life science industry from leading positions in Novo Nordisk A/S and as the former CEO of diagnostics company Dako A/S and biotech company Zealand Pharma A/S. Currently, Britt Meelby Jensen is the CEO of the medtech company Atos Medical AB and is member of the Board of Directors of the Hempel Foundation.

You can download this company announcement (pdf).

Financial Reports

Get the latest annual & quarterly reports
Read more

Annual Key Figures

Get an overview of Ambu's key figures
Read more


Get the latest investor presentations and webcasts
Read more


Learn more about Ambu's present strategy
Read more

Upcoming events


Dec. 2019

SEB Q4 roadshow

3 December 2019


Dec. 2019

ABG Q4 roadshow

Düsseldorf, Cologne, Stuttgart and Hamburg
4-5 December 2019


Dec. 2019

Ordinary Annual General Meeting 2018/19

​The Annual General Meeting 2018/19 will be held on Tuesday 17 December 2019 at 13.00 (CET) at Tivoli Hotel & Congress Center, Arni Magnussons Gade 2, 1577 Copenhagen V, Denmark.

You can download the notice and

The meeting will be live streamed on and will be available as on-demand video after the meeting.

News from Ambu

Sign up and receive news and company announcements from Ambu

Sign up